Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-365176ec901be3a749e148c628fa3afe"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-365176ec901be3a749e148c628fa3afe"/>
<resource>
<Composition>
<id value="composition-en-365176ec901be3a749e148c628fa3afe"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-365176ec901be3a749e148c628fa3afe"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-365176ec901be3a749e148c628fa3afe</b></p><a name="composition-en-365176ec901be3a749e148c628fa3afe"> </a><a name="hccomposition-en-365176ec901be3a749e148c628fa3afe"> </a><a name="composition-en-365176ec901be3a749e148c628fa3afe-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/14/969/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - scenesse</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/14/969/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp365176ec901be3a749e148c628fa3afe"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - scenesse"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What SCENESSE is and what it is used for</li><li>What you need to know before you receive SCENESSE</li><li>How SCENESSE is given</li><li>Possible side effects</li><li>How SCENESSE is stored</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What scenesse is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What scenesse is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>SCENESSE contains the active substance afamelanotide (as acetate). Afamelanotide is a synthetic form of a body hormone called alpha-melanocyte stimulating hormone ( -MSH). Afamelanotide works in a way similar to the natural hormone, by making skin cells produce eumelanin which is a brown-black type of melanin pigment in the body.</p><p>Afamelanotide is used to increase the tolerance to sunlight in adults with a confirmed diagnosis of erythropoietic protoporphyria (EPP). EPP is a condition in which patients have an increased sensitivity to sunlight, which can cause toxic effects such as pain and burning. By increasing the amount of eumelanin, SCENESSE can help to delay the onset of pain due to skin photosensitivity (sensitive to sunlight).</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take scenesse"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take scenesse"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not use SCENESSE</p><ul><li>if you are allergic to afamelanotide or any of the other ingredients of this medicine (listed in section 6).</li><li>if you have any severe condition of the liver.</li><li>if you have liver problems.</li><li>if you have kidney problems.</li></ul><p>Warnings and precautions</p><p>Talk to your doctor before receiving SCENESSE if you have or have ever had:</p><ul><li>heart problems or severe breathing problems;</li><li>gastrointestinal problems;</li><li>diabetes;</li><li>Cushing s disease (a hormone disorder where the body produces too much of the hormone cortisol);</li><li>Addison s disease (a disorder of the adrenal glands causing a lack of some hormones);</li><li>Peutz-Jeghers syndrome (a disorder that causes blockage of the bowel and where your hands, soles of your feet and surface of your lips may have brown freckles);</li><li>epilepsy (or have been told that you are at risk of having fits);</li><li>anaemia (low counts of red blood cells in your blood);</li><li>melanoma (an aggressive type of skin cancer), including in-situ melanoma, e.g. lentigo maligna; or if you have certain inherited conditions that increase the risk of developing a melanoma;</li><li>skin cancer of the types, basal cell carcinoma or squamous cell carcinoma (inclusive of carcinoma in situ, e.g. Bowen s disease), Merkel cell carcinoma or other malignant or premalignant skin problems.</li></ul><p>Talk to your doctor before receiving SCENESSE if you are over 70 years of age.</p><p>If you have ever had any of these conditions your doctor may have to monitor you more closely during your treatment.</p><p>Sun protection</p><p>Do not change the sun protection measures you normally follow to manage your EPP and according to your skin phototype (UV sensitivity). Keep in mind that increased exposure to UV light will contribute to skin cancer development.</p><p>Skin monitoring</p><p>Because this medicine increases eumelanin, in most treated patients the skin will darken. This is an expected response to this medicine, and the darkening will slowly fade unless another implant is used.</p><p>Your doctor will need to regularly check your skin (full body) to monitor changes in moles (e.g. darkening) or other skin abnormalities. This is recommended to be performed every 6 months.</p><p>Please inform your doctor about new or changing skin abnormalities. Arrange for an early appointment with your porphyria specialist if pigmented lesions like moles grow or if other growing, non-healing, weeping, plaque-like, wart-like, or ulcerated lesions appear. A referral to a dermatology specialist might be necessary.</p><p>Children and adolescents</p><p>This medicine should not be given to children and adolescents under 18 years of age because it has not been tested in this age group.</p><p>Other medicines and SCENESSE</p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>Tell your doctor if you are taking anticoagulant medicines used to prevent blood clots. These may include warfarin, acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever or to prevent blood clotting) and a group of medicines called non-steroidal anti- inflammatory drug (NSAIDs), used to treat common ailments, such as arthritis, headaches, mild fever, rheumatism and sore throats. This is because patients taking such medicines may experience increased bruising or bleeding at the site of the implant.</p><p>Pregnancy and breastfeeding</p><p>If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, you should not receive SCENESSE, since it is not known how it will affect your unborn baby or the breastfed infant.</p><p>Women who could become pregnant should use adequate contraception such as oral contraceptives, diaphragm plus spermicide, intrauterine device (also known as a coil) during treatment and for three months after the last SCENESSE implantation.</p><p>Driving and using machines</p><p>There is a risk of feeling drowsy and tired when using this medicine, especially within 72 hours of administration. If you are affected, do not drive or use any tools or machines. If you suffer from continued drowsiness, then you should speak to your doctor.</p></div>
</text>
</section>
<section>
<title value="3. How to take scenesse"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take scenesse"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>The implant will be inserted by a doctor who has been trained in the administration procedure. The doctor will decide with you the most suitable time and the site for inserting the implant.</p><p>One implant is injected every 2 months during the spring and summer months. Three implants per year are recommended, depending on the length of effect required. However, this number should not exceed more than 4 per year.</p><p>The implant is given as injection under your skin using a catheter tube and needle (subcutaneous use). Before inserting this medicine, your doctor may decide to give you a local anaesthetic to numb the area where the implant is to be inserted. The implant is inserted directly under the skin folds on your waist or abdomen in an area known as the supra-iliac crest.</p><p>At the end of the insertion procedure, you may be able to feel the implant under your skin. Over time the implant will be absorbed by the body, this will happen within 50 to 60 days after implantation.</p><p>If you experience discomfort and are concerned, speak to your doctor. The implant may be removed by a simple surgical procedure if needed.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The following side effects are considered to be:</p><p>Very common (may affect more than 1 in 10 people):</p><ul><li>nausea (feeling sick),</li><li>headache.</li></ul><p>Common (may affect up to 1 in 10 people):</p><ul><li>flu, upper respiratory tract infection (colds),</li><li>general changes to the skin including darkening of freckles and moles,</li><li>rash with small blisters, itch, rash, red rash, itchy rash,</li><li>dizziness, drowsiness and migraine (severe headache),</li><li>hot flushes, flushing, feeling hot and redness of the skin,</li><li>abdominal (tummy) pain, toothache, diarrhoea and vomiting,</li><li>pain in arms and legs, pain or weakness in muscles and bones, back pain,</li><li>fatigue, pain, fever, reactions at the implant site including pain, bruising, swelling, bleeding, itching and changes to the colour of overlying skin, flu-like illness, cough, blocked nose, inflamed nose and throat.</li></ul><p>Uncommon (may affect up to 1 in 100 people):</p><ul><li>urinary tract infection, infected hair follicle, infection in stomach and intestines,</li><li>hypersensitivity,</li><li>decreased or increased appetite,</li><li>depressed mood including depression, inability to sleep, poor quality sleep,</li><li>fainting, fainting sensation, weakness, inability to get legs comfortable, disturbance of balance,</li><li>dry eye, eye pain, red eyes, difficulty focusing on objects, sensitivity in eyes to light, ringing in ears,</li><li>palpitations, bruising, bleeding, hight blood pressure,</li><li>blocked sinuses,</li><li>inflamed stomach and intestines, heartburn, irritable bowel syndrome, wind, lip swelling, reduce sense of touch in the mouth, gum pain,</li><li>acne, eczema, red swelling on skin, dry skin, hair colour changes, excessive sweating, pigmentation in nails, colouration on lip, skin peeling, skin burning sensation, changes to the colour of the skin including loss of colour, oily skin, hives,</li><li>joint stiffness, stiffness of muscle and bones, sudden muscle contraction, sore muscle,</li><li>breast tenderness, irregular period, painful period,</li><li>chills, feeling hot, hangover, malaise, swelling in legs or hands,</li><li>abnormal liver function tests, decreased iron binding, increased sugar level, decreased blood iron level, blood in urine,</li><li>fall and wound,</li><li>device expulsion.</li></ul><p>Rare (may affect up to 1 in 1000 people):</p><ul><li>fungal infection,</li><li>decrease white blood cells,</li><li>increased cholesterol,</li><li>confusion, headache following injury, abnormal taste sensation,</li><li>swollen eye lids,</li><li>fast hart rate,</li><li>irregular bowel movements, inflamed lips, discoloured gums, lips and tongue,</li><li>red or brownish nodules on the skin (called Lichen planus ), vitiligo,</li><li>heavy prolonged period, discharge from vagina, decreased sex drive,</li><li>increase in body weight,</li><li>wound complication, nausea following implant insertion.</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store scenesse"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store scenesse"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>This medicine must not be used after the expiry date which is stated on the vial and the outer carton. Your doctor will check the expiry date before an implant is used.</p><p>Store in a refrigerator (2oC - 8oC).</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What SCENESSE contains</p><ul><li>The active substance is afamelanotide. One implant contains 16 mg of afamelanotide (as acetate).</li><li>The other ingredient is poly (D,L-lactide-co-glycolide).</li></ul><p>What SCENESSE looks like and contents of the pack</p><p>The implant is a solid white to off-white rod approximately 1.7 cm in length and 1.5 mm in diameter in an amber glass vial sealed with a PTFE coated rubber stopper. Pack size of one vial containing one implant.</p><p>Marketing Authorisation Holder</p><p>CLINUVEL EUROPE LIMITED 10 Earlsfort Terrace Dublin 2 D02 TIreland Tel: +353 1513 <a href="mailto:4mail@clinuvel.com">4mail@clinuvel.com</a></p><p>Manufacturer</p><p>CLINUVEL EUROPE LIMITED Alexandra House The Sweepstakes Ballsbridge Dublin 4 D04 C7H2 Ireland</p><p>This leaflet was last revised in</p><p>This medicine has been authorised under exceptional circumstances . This means that because of the rarity of this disease, for scientific reasons, and for ethical reasons it has been impossible to get complete information on this medicine. The European Medicines Agency will review any new information on this medicine every year and this leaflet will be updated as necessary.</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp365176ec901be3a749e148c628fa3afe"/>
<resource>
<MedicinalProductDefinition>
<id value="mp365176ec901be3a749e148c628fa3afe"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp365176ec901be3a749e148c628fa3afe"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp365176ec901be3a749e148c628fa3afe</b></p><a name="mp365176ec901be3a749e148c628fa3afe"> </a><a name="hcmp365176ec901be3a749e148c628fa3afe"> </a><a name="mp365176ec901be3a749e148c628fa3afe-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/14/969/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: SCENESSE 16 mg implant</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/14/969/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="SCENESSE 16 mg implant"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
